ArticleFrontiers in pharmacology2023
Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Assessment and detection of nucleotide excision repair capability in human cells: a critical review of current functional methods.Molecular biology reports · 2026Review
- Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase-initiated genetically engineered mouse model.The Journal of clinical investigation · 2026Article
- Targeting Skin Cancer with Natural Bioactive Compounds: From Molecular Mechanisms to Application Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Targeted Delivery of Triptolide Via Folate-Functionalized Pluronic Micelles Enhances Anti-Melanoma Activity by Inducing Reactive Oxygen Species Accumulation.BioMed research international · 2026Article
- Review
- Naturally Derived SENP1 Inhibitors with Anticancer Activity.International journal of molecular sciences · 2025Review
- Efficacy of Minnelide in a Next-Generation Dual-Recombinase Regulated Genetically Engineered Mouse Model of CIC::DUX4 Sarcoma.bioRxiv : the preprint server for biology · 2025Article
- Utilization of natural products in diverse pathogeneses of diseases associated with single or double DNA strand damage repair.Chinese medicine · 2025Review
- Triptolide reverses cis‑diamminedichloroplatinum resistance in esophageal squamous cell carcinoma by suppressing glycolysis and causing mitochondrial malfunction.Molecular medicine reports · 2025Article
- Review
- Triptolide suppresses melanoma cell growthJournal of Cancer · 2024Article
- Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy.Frontiers in immunology · 2023Review
- Advances in the treatment of pancreatic cancer with traditional Chinese medicine.Frontiers in pharmacology · 2023Review
- Triptolide enhances anti-cancer activities of irinotecan in human colon cancer HT-29 cellsIntegrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.